BenevolentAI SA
AEX:BAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BenevolentAI SA
Total Liabilities
BenevolentAI SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BenevolentAI SA
AEX:BAI
|
Total Liabilities
£29.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Total Liabilities
£44.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Total Liabilities
$65.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Total Liabilities
$3.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Total Liabilities
£95.7m
|
CAGR 3-Years
40%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Total Liabilities
£161.5m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
BenevolentAI SA
Glance View
BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. The firm through the combined capabilities of its AI platform, scientific ability and wet-lab facilities deliver new drug candidates with a higher probability of clinical success than those developed using traditional methods. The company has an array of scientifically validated discoveries. The Company, through its BenevolentAI Platform, offers in-house pipeline of over 20 disease programs, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies, such as AstraZeneca, as well as other research and charitable institutions.
See Also
What is BenevolentAI SA's Total Liabilities?
Total Liabilities
29.6m
GBP
Based on the financial report for Dec 31, 2023, BenevolentAI SA's Total Liabilities amounts to 29.6m GBP.
What is BenevolentAI SA's Total Liabilities growth rate?
Total Liabilities CAGR 1Y
-7%
Over the last year, the Total Liabilities growth was -7%.
